open access

Vol 45, No 1 (2007)
Original paper
Submitted: 2011-12-19
Published online: 2007-03-24
Get Citation

Expression of class III beta-tubulin in malignant epithelial tumours: an immunohistochemical study using TU-20 and TuJ-1 antibodies.

TomĂĄs JirĂĄsek, Eva PĂ­sarĂ­ kovĂĄ, VladimĂ­r ViklickĂ˝, VĂĄclav Mandys
Folia Histochem Cytobiol 2007;45(1):41-45.

open access

Vol 45, No 1 (2007)
ORIGINAL PAPERS
Submitted: 2011-12-19
Published online: 2007-03-24

Abstract

Class III beta-tubulin has been discovered as a marker of early phases of neuronal differentiation in developmental conditions, as well as in different tumours of neuronal origin. More recently, the expression of class III beta-tubulin molecule has been described as a marker of different types of malignant epithelial tumours. This study attempts to compare the immunostaining features of two different mouse monoclonal antibodies TU-20 and TuJ-1, both detecting class III beta-tubulin, in a group of twenty bioptically evaluated carcinomas of various sites. The proposal that class III beta-tubulin expression can correlate with the degree of tumour differentiation and thus could be potentially used as predictive marker of prognosis has been previously done; one of aims of our study was to confirm this hypothesis. Our results showed that both TuJ- 1 and TU-20 antibodies displayed similar immunostaining profile and pattern within individual tumours. Surprisingly, we discovered that only 50% of tumours included in our group showed expression of class III beta-tubulin, however, positive immunoreaction did not correspond with the degree of differentiation of individual tumours. In our group of carcinomas, the class III beta-tubulin positivity was not related to the tumour site, histologic type of tumour or its grade.

Abstract

Class III beta-tubulin has been discovered as a marker of early phases of neuronal differentiation in developmental conditions, as well as in different tumours of neuronal origin. More recently, the expression of class III beta-tubulin molecule has been described as a marker of different types of malignant epithelial tumours. This study attempts to compare the immunostaining features of two different mouse monoclonal antibodies TU-20 and TuJ-1, both detecting class III beta-tubulin, in a group of twenty bioptically evaluated carcinomas of various sites. The proposal that class III beta-tubulin expression can correlate with the degree of tumour differentiation and thus could be potentially used as predictive marker of prognosis has been previously done; one of aims of our study was to confirm this hypothesis. Our results showed that both TuJ- 1 and TU-20 antibodies displayed similar immunostaining profile and pattern within individual tumours. Surprisingly, we discovered that only 50% of tumours included in our group showed expression of class III beta-tubulin, however, positive immunoreaction did not correspond with the degree of differentiation of individual tumours. In our group of carcinomas, the class III beta-tubulin positivity was not related to the tumour site, histologic type of tumour or its grade.
Get Citation
About this article
Title

Expression of class III beta-tubulin in malignant epithelial tumours: an immunohistochemical study using TU-20 and TuJ-1 antibodies.

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 45, No 1 (2007)

Article type

Original paper

Pages

41-45

Published online

2007-03-24

Bibliographic record

Folia Histochem Cytobiol 2007;45(1):41-45.

Authors

TomĂĄs JirĂĄsek
Eva PĂ­sarĂ­ kovĂĄ
VladimĂ­r ViklickĂ˝
VĂĄclav Mandys

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl